242 related articles for article (PubMed ID: 29191715)
21. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
Mei MG; Cao TM; Chen L; Song JY; Siddiqi T; Cai JL; Farol LT; Al Malki MM; Salhotra A; Aldoss I; Palmer J; Herrera AF; Zain J; Popplewell LL; Chen RW; Rosen ST; Forman SJ; Kwak L; Nademanee AP; Budde LE
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1861-1869. PubMed ID: 28733266
[TBL] [Abstract][Full Text] [Related]
23. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
Galimberti S; Palumbo GA; Caracciolo F; Benedetti E; Pelosini M; Brizzi S; Ciabatti E; Fazzi R; Stelitano C; Quintana G; Conte E; Tibullo D; Di Raimondo F; Petrini M
J Chemother; 2007 Jun; 19(3):315-21. PubMed ID: 17594928
[TBL] [Abstract][Full Text] [Related]
26. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.
Hosein PJ; Sandoval-Sus JD; Goodman D; Arteaga AG; Reis I; Hoffman J; Stefanovic A; Rosenblatt JD; Lossos IS
Am J Hematol; 2015 Jun; 90(6):E111-6. PubMed ID: 25737247
[TBL] [Abstract][Full Text] [Related]
27. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Ruan J; Martin P; Christos P; Cerchietti L; Tam W; Shah B; Schuster SJ; Rodriguez A; Hyman D; Calvo-Vidal MN; Smith SM; Svoboda J; Furman RR; Coleman M; Leonard JP
Blood; 2018 Nov; 132(19):2016-2025. PubMed ID: 30181173
[TBL] [Abstract][Full Text] [Related]
28. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
Romaguera JE; Fayad LE; Feng L; Hartig K; Weaver P; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak L; Wang M
Br J Haematol; 2010 Jul; 150(2):200-8. PubMed ID: 20528872
[TBL] [Abstract][Full Text] [Related]
29. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Karmali R; Switchenko JM; Goyal S; Shanmugasundaram K; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Epperla N; Mathews S; Burkart M; Sawalha Y; Hill BT; Ghosh N; Park SI; Bond DA; Maddocks KJ; Badar T; Fenske TS; Hamadani M; Guo J; Malecek M; Kahl BS; Martin P; Blum KA; Flowers CR; Cohen JB
Am J Hematol; 2021 Nov; 96(11):1374-1384. PubMed ID: 34324220
[TBL] [Abstract][Full Text] [Related]
30. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
Jeong SH; Moon JH; Kim JS; Yang DH; Park Y; Cho SG; Kwak JY; Eom HS; Won JH; Hong JS; Oh SY; Lee HS; Kim SJ
Ann Hematol; 2015 Apr; 94(4):617-25. PubMed ID: 25465233
[TBL] [Abstract][Full Text] [Related]
31. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.
Spurgeon SE; Pindyck T; Okada C; Chen Y; Chen Z; Mater E; Abbi K; Epner EM
Leuk Lymphoma; 2011 Aug; 52(8):1488-94. PubMed ID: 21623691
[TBL] [Abstract][Full Text] [Related]
32. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
[TBL] [Abstract][Full Text] [Related]
33. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
34. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
35. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review.
Alwasaidi TA; Hamadah A; Altouri S; Tay J; McDiarmid S; Faught C; Allan D; Huebsch L; Bredeson C; Bence-Bruckler I
Cancer Med; 2015 Dec; 4(12):1817-27. PubMed ID: 26432256
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
[TBL] [Abstract][Full Text] [Related]
38. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
39. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
[TBL] [Abstract][Full Text] [Related]
40. Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry
Obr A; Prochazka V; Papajik T; Klener P; Janikova A; Salek D; Belada D; Pytlík R; Sykorova A; Mocikova H; Simkovic M; Campr V; Dlouha J; Furst T; Trněný M
Leuk Lymphoma; 2019 Mar; 60(3):748-755. PubMed ID: 30188225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]